US5587308A
(en)
*
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
US5869305A
(en)
*
|
1992-12-04 |
1999-02-09 |
The University Of Pittsburgh |
Recombinant viral vector system
|
US6686200B1
(en)
*
|
1993-08-31 |
2004-02-03 |
Uab Research Foundation |
Methods and compositions for the large scale production of recombinant adeno-associated virus
|
US5834441A
(en)
*
|
1993-09-13 |
1998-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral (AAV) liposomes and methods related thereto
|
WO1997003703A1
(en)
*
|
1995-07-21 |
1997-02-06 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
US6652850B1
(en)
*
|
1993-09-13 |
2003-11-25 |
Aventis Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
FR2716459B1
(fr)
*
|
1994-02-22 |
1996-05-10 |
Univ Paris Curie |
Système hôte-vecteur utilisable en thérapie génique.
|
FR2716893B1
(fr)
*
|
1994-03-03 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, leur préparation et leur utilisation thérapeutique.
|
CA2187626C
(en)
*
|
1994-04-13 |
2009-11-03 |
Michael G. Kaplitt |
Aav-mediated delivery of dna to cells of the nervous system
|
US5658785A
(en)
*
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US6342390B1
(en)
|
1994-11-23 |
2002-01-29 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
|
US6924128B2
(en)
*
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
US6383814B1
(en)
*
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
US6110456A
(en)
*
|
1995-06-07 |
2000-08-29 |
Yale University |
Oral delivery or adeno-associated viral vectors
|
US5646034A
(en)
*
|
1995-06-07 |
1997-07-08 |
Mamounas; Michael |
Increasing rAAV titer
|
US6207457B1
(en)
*
|
1995-09-08 |
2001-03-27 |
Avigen, Inc. |
Targeted nucleotide sequence delivery and integration system
|
US6086913A
(en)
*
|
1995-11-01 |
2000-07-11 |
University Of British Columbia |
Liposomal delivery of AAV vectors
|
CA2279669A1
(en)
*
|
1995-12-15 |
1997-06-16 |
Enzo Therapeutics, Inc. |
Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
|
US5858351A
(en)
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
DE19608753C1
(de)
*
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
US6245735B1
(en)
|
1996-07-29 |
2001-06-12 |
The Brigham And Women's Hospital, Inc. |
Methods and products for treating pseudomonas infection
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
AU4645697A
(en)
|
1996-09-11 |
1998-04-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aav4 vector and uses thereof
|
CA2797661C
(en)
|
1997-04-24 |
2015-06-16 |
University Of Washington |
Targeted gene modification by parvoviral vectors
|
US6156303A
(en)
*
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6995006B2
(en)
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6642051B1
(en)
*
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
US6346415B1
(en)
|
1997-10-21 |
2002-02-12 |
Targeted Genetics Corporation |
Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
|
WO1999020773A2
(en)
*
|
1997-10-21 |
1999-04-29 |
Targeted Genetics Corporation |
TRANSCRIPTIONALLY-ACTIVATED AAV INVERTED TERMINAL REPEATS (ITRs) FOR USE WITH RECOMBINANT AAV VECTORS
|
EP1042494A1
(de)
*
|
1997-12-23 |
2000-10-11 |
Introgene B.V. |
Chimere rekombinante vektoren abgeleitet von adeno-assoziiertem virus und adenovirus für die chromosomale integration von fremd-dns in zielzellen
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
US6294379B1
(en)
*
|
1998-02-25 |
2001-09-25 |
The Regents Of The University Of California |
Efficient AAV vectors
|
JP2002509716A
(ja)
|
1998-03-31 |
2002-04-02 |
ユニバーシティ テクノロジー コーポレイション |
テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
|
DK1071806T3
(da)
*
|
1998-04-24 |
2004-07-19 |
Univ Florida |
Rekombinant adeno-associeret virus-vektor, der koder for alpha-1-antitrypsin i genterapi
|
WO1999057133A2
(en)
|
1998-05-06 |
1999-11-11 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Inhibitors of nf-kb activation
|
US6146874A
(en)
*
|
1998-05-27 |
2000-11-14 |
University Of Florida |
Method of preparing recombinant adeno-associated virus compositions
|
US6984517B1
(en)
|
1998-05-28 |
2006-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector and uses thereof
|
JP4060531B2
(ja)
*
|
1998-05-28 |
2008-03-12 |
アメリカ合衆国 |
Aav5ベクターおよびその使用
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
AU1128400A
(en)
|
1998-10-22 |
2000-05-08 |
Medical College Of Georgia Institute, Inc. |
Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
|
US7129043B1
(en)
*
|
1998-10-22 |
2006-10-31 |
Duke University |
Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
|
US6468793B1
(en)
|
1998-10-23 |
2002-10-22 |
Florida State University Research Foundation |
CFTR genes and proteins for cystic fibrosis gene therapy
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
CA2348382C
(en)
|
1998-11-10 |
2013-09-17 |
The University Of North Carolina At Chapel Hill |
Chimeric parvovirus vectors and methods of making and administering the same
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
US6537540B1
(en)
*
|
1999-05-28 |
2003-03-25 |
Targeted Genetics Corporation |
Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
|
EP1196609A2
(de)
|
1999-06-28 |
2002-04-17 |
Oklahoma Medical Research Foundation |
Katalytisch wirksame rekombinierte memapsin und verfahren zur verwendung davon
|
AU781958C
(en)
*
|
1999-08-09 |
2006-03-30 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
|
AU7879000A
(en)
*
|
1999-10-12 |
2001-04-23 |
University Of North Carolina At Chapel Hill, The |
Adeno-associated virus vectors encoding factor viii and methods of using the same
|
WO2001059450A2
(en)
|
2000-02-08 |
2001-08-16 |
Sangamo Biosciences, Inc. |
Cells expressing zinc finger protein for drug discovery
|
AU2001240018A1
(en)
|
2000-03-03 |
2001-09-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral compositions and methods
|
US6855314B1
(en)
|
2000-03-22 |
2005-02-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector for transducing brain cells and lung cells
|
US6506600B2
(en)
|
2000-03-22 |
2003-01-14 |
University Of Arkansas |
Secreting products from skin by adeno-associated virus (AAV) gene transfer
|
WO2002092619A2
(en)
*
|
2001-05-14 |
2002-11-21 |
The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified growth hormone
|
WO2002094854A2
(en)
|
2001-05-21 |
2002-11-28 |
The Brigham And Women's Hospital, Inc. |
P.aeruginosa mucoid exopolysaccharide specific binding peptides
|
US7119172B2
(en)
|
2001-05-21 |
2006-10-10 |
The Brigham And Women's Hospital, Inc. |
P. aeruginosa mucoid exopolysaccharide specific binding peptides
|
AU2002329176A1
(en)
|
2001-05-25 |
2002-12-23 |
The Trustees Of The University Of Pennsylvania |
Targeted particles and methods of using the same
|
JP4252446B2
(ja)
|
2001-06-22 |
2009-04-08 |
フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) |
Abinにより媒介される肝炎防護
|
WO2003027247A2
(en)
|
2001-09-24 |
2003-04-03 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
CA2472927A1
(en)
|
2002-01-10 |
2003-07-17 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
A novel splice variant of myd88 and uses thereof
|
AU2003267949A1
(en)
|
2002-03-15 |
2003-12-31 |
U.S. Government As Represented By The Department Of Veterans Affairs |
Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
|
US6825263B2
(en)
*
|
2002-04-08 |
2004-11-30 |
Dow Corning Corporation |
Curable coating compositions from emulsions of elastomeric polymers and polyurethane dispersions
|
MXPA04010282A
(es)
|
2002-04-18 |
2005-08-18 |
Acuity Pharmaceuticals Inc |
Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
KR20050083855A
(ko)
|
2002-11-01 |
2005-08-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
HIF-1 알파의 siRNA 억제를 위한 조성물 및 방법
|
JP4939055B2
(ja)
|
2002-11-13 |
2012-05-23 |
トマス ジェファソン ユニバーシティ |
癌の診断および治療のための組成物および方法
|
US20040225077A1
(en)
|
2002-12-30 |
2004-11-11 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
EP2251434B1
(de)
|
2003-01-16 |
2014-07-30 |
The Trustees of The University of Pennsylvania |
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
|
WO2005017101A2
(en)
|
2003-05-19 |
2005-02-24 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Avian adenoassociated virus (aaav) and uses thereof
|
EP3222715A1
(de)
|
2003-08-08 |
2017-09-27 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen für gezielte spaltung und rekombination
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
WO2005028630A2
(en)
|
2003-09-19 |
2005-03-31 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
WO2005056807A2
(en)
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
EP1713938A2
(de)
|
2004-02-09 |
2006-10-25 |
Thomas Jefferson University |
Diagnose und behandlung von krebserkrankungen mit oder nahe mit krebs in zusammenhang stehenden chromosomalen merkmalen lokalisierter microrna
|
EP2365077B1
(de)
|
2004-03-12 |
2013-05-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA-Agenten zum VEGF-Targeting
|
JP2007529223A
(ja)
*
|
2004-03-15 |
2007-10-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
選択的スプライシングを用いて真核細胞においてポリペプチドマルチマーを発現するための方法および構築物
|
CA2561565C
(en)
|
2004-04-08 |
2013-11-26 |
Sangamo Biosciences, Inc. |
Methods for repression of phospholamban gene and modulating cardiac contractility
|
WO2006036465A2
(en)
*
|
2004-09-03 |
2006-04-06 |
University Of Florida |
Compositions and methods for treating cystic fibrosis
|
CA2579677A1
(en)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
CA2591544A1
(en)
*
|
2004-12-15 |
2006-06-22 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
CA2599004C
(en)
|
2005-02-28 |
2015-05-26 |
Sangamo Biosciences, Inc. |
Anti-angiogenic methods and compositions
|
BRPI0610075B8
(pt)
|
2005-04-22 |
2021-06-22 |
Evonik Degussa Gmbh |
estruturas de poliméro de absorção de água, seus usos, processos para tratamento da superfície das mesmas, compostos, processos para produção dos mesmos, produtos compreendendo as estruturas poliméricas e usos de combinações de óxidos de metal e sais de metal de cátion de metal bivalente ou trivalente
|
WO2006119432A2
(en)
|
2005-04-29 |
2006-11-09 |
The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services |
Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
|
KR101419729B1
(ko)
|
2005-07-26 |
2014-07-17 |
상가모 바이오사이언스 인코포레이티드 |
외래 핵산 서열의 표적화된 통합 및 발현
|
CN101296702B
(zh)
|
2005-09-12 |
2012-11-28 |
俄亥俄州立大学研究基金会 |
用于诊断或治疗bcl2相关癌症的组合物和方法
|
AU2006326940B2
(en)
|
2005-12-22 |
2012-04-19 |
Vib Vzw |
Means and methods for mediating protein interference
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
JP2009521234A
(ja)
|
2005-12-22 |
2009-06-04 |
エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. |
補体系を制御する組成および方法
|
CA2633674A1
(en)
|
2006-01-05 |
2007-07-19 |
The Ohio State University Research Foundation |
Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
|
EP1968622B1
(de)
|
2006-01-05 |
2014-08-27 |
The Ohio State University Research Foundation |
Mikro-rna-expressions-anomalien in pankreas- und azinus-tumoren
|
EP2487257B1
(de)
|
2006-01-05 |
2015-07-01 |
The Ohio State University Research Foundation |
Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von festen Krebsen
|
US20100286232A1
(en)
|
2006-03-02 |
2010-11-11 |
The Ohio State University |
Microrna expression profile associated with pancreatic cancer
|
ES2446362T3
(es)
|
2006-03-20 |
2014-03-07 |
The Ohio State University Research Foundation |
Huellas de microARN durante megacariocipoyesis humana
|
SG170780A1
(en)
|
2006-03-31 |
2011-05-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of eg5 gene
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
ES2874149T3
(es)
|
2006-05-11 |
2021-11-04 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen PCSK9
|
CA2652770A1
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
WO2007139898A2
(en)
|
2006-05-25 |
2007-12-06 |
Sangamo Biosciences, Inc. |
Variant foki cleavage half-domains
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
WO2007146953A2
(en)
|
2006-06-12 |
2007-12-21 |
Exegenics, Inc., D/B/A Opko Health, Inc. |
Compositions and methods for sirna inhibition of angiogenesis
|
WO2008008430A2
(en)
|
2006-07-13 |
2008-01-17 |
The Ohio State University Research Foundation |
Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
|
JP5623740B2
(ja)
*
|
2006-07-25 |
2014-11-12 |
セラドン・コーポレーション |
遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
|
US7872118B2
(en)
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
EP2126141A4
(de)
|
2007-03-15 |
2010-08-11 |
Univ Cleveland Hospitals |
Screening, diagnose, behandlung und prognose pathophysiologischer zustände durch rna-regulation
|
CN101678082B
(zh)
|
2007-03-26 |
2013-06-19 |
再生医药有限公司 |
使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
AP2014007971A0
(en)
|
2007-03-29 |
2014-09-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
EP2319926B1
(de)
|
2007-07-05 |
2016-08-31 |
Arrowhead Research Corporation |
DSRNA zur Behandlung viraler Infektionen
|
KR101510778B1
(ko)
|
2007-07-12 |
2015-04-10 |
상가모 바이오사이언스 인코포레이티드 |
알파 1,6 당전이효소(fut8) 유전자 발현을 비활성화시키기 위한 방법 및 조성물
|
WO2009012263A2
(en)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
AU2008282318B2
(en)
|
2007-07-31 |
2014-02-27 |
The Ohio State University Research Foundation |
Methods for reverting methylation by targeting methyltransferases
|
CN101835902B
(zh)
|
2007-08-03 |
2014-03-26 |
俄亥俄州立大学研究基金会 |
编码ncrna的超保守区域
|
CA2926831A1
(en)
|
2007-08-22 |
2009-02-26 |
The Ohio State University Research Foundation |
Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
|
EP3138926A3
(de)
|
2007-09-06 |
2017-04-05 |
The Ohio State University Research Foundation |
Mirna-signaturen in menschlichem ovarialkarzinom
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
CN103937876B
(zh)
|
2007-10-11 |
2016-08-17 |
俄亥俄州立大学研究基金会 |
用于诊断和治疗食管腺癌的方法和组合物
|
EP2612868B1
(de)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunsuppressive Polypeptide und Nucleinsäuren
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
EP2244740A1
(de)
|
2008-02-19 |
2010-11-03 |
Celladon Corporation |
Zusammensetzungen zur verbesserten aufnahme von virusvektoren in das myokard
|
EA201301171A1
(ru)
|
2008-03-05 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов eg5 и vegf
|
KR101802393B1
(ko)
|
2008-06-10 |
2017-11-28 |
상가모 테라퓨틱스, 인코포레이티드 |
Bax- 및 bak-결함 세포주들의 제조 방법 및 조성물
|
CN102159722B
(zh)
|
2008-08-22 |
2014-09-03 |
桑格摩生物科学股份有限公司 |
用于靶向单链切割和靶向整合的方法和组合物
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
WO2010036962A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
AU2009307677C1
(en)
|
2008-10-20 |
2022-09-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
DK2977053T3
(en)
|
2008-11-30 |
2017-10-09 |
Immusant Inc |
COMPOSITIONS AND PROCEDURES FOR TREATMENT OF CELLIA
|
CA2745832A1
(en)
|
2008-12-04 |
2010-06-10 |
Opko Ophthalmics, Llc |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
NZ593618A
(en)
|
2008-12-10 |
2013-02-22 |
Alnylam Pharmaceuticals Inc |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
CA2934285C
(en)
|
2009-02-04 |
2018-11-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
CN104922699B
(zh)
|
2009-03-12 |
2020-07-24 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
|
CA2755870C
(en)
|
2009-03-20 |
2019-04-09 |
Angioblast Systems, Inc. |
Production of reprogrammed pluripotent cells
|
CA2756833C
(en)
|
2009-04-09 |
2019-11-19 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
WO2010129021A1
(en)
|
2009-05-02 |
2010-11-11 |
Genzyme Corporation |
Gene therapy for neurodegenerative disorders
|
EP2451475A2
(de)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Selbstreplizierende rna-moleküle und ihre verwendung
|
WO2011008974A2
(en)
|
2009-07-15 |
2011-01-20 |
Novartis Ag |
Rsv f protein compositions and methods for making same
|
US9234016B2
(en)
|
2009-07-28 |
2016-01-12 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for treating trinucleotide repeat disorders
|
EP2810643A3
(de)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen aus Lipidformulierung und Verfahren zur Hemmung der Expression eines Gens aus dem Ebola-Virus
|
BR112012009801A8
(pt)
|
2009-10-30 |
2016-08-30 |
Cns Therapeutics Inc |
Polipeptídeo neurturina e variante de neurturina
|
CA2779512C
(en)
|
2009-11-02 |
2017-01-17 |
Leonard H. Rome |
Vault complexes for cytokine delivery
|
US8551781B2
(en)
|
2009-11-19 |
2013-10-08 |
The Regents Of The University Of California |
Vault complexes for facilitating biomolecule delivery
|
RU2012127772A
(ru)
|
2009-12-04 |
2014-01-10 |
ОПКО ОФТЭЛМИКС, ЭлЭлСи |
Композиции и способы для ингибирования vegf
|
CA2788560A1
(en)
|
2010-02-08 |
2011-08-11 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
US9255259B2
(en)
|
2010-02-09 |
2016-02-09 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
CA2792291A1
(en)
|
2010-03-29 |
2011-10-06 |
Kumamoto University |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
EP2571512B1
(de)
|
2010-05-17 |
2017-08-23 |
Sangamo BioSciences, Inc. |
Neue dna-bindende proteine und verwendungen davon
|
US9944671B2
(en)
|
2010-06-02 |
2018-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2012006552A1
(en)
|
2010-07-09 |
2012-01-12 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
WO2012015938A2
(en)
|
2010-07-27 |
2012-02-02 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
US20120225034A1
(en)
|
2010-09-02 |
2012-09-06 |
Universite De Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
WO2012047598A1
(en)
|
2010-09-27 |
2012-04-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
MX363307B
(es)
|
2010-10-11 |
2019-03-20 |
Novartis Ag Star |
Plataformas para suministro de antigenos.
|
EP2649182A4
(de)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
|
EP2648763A4
(de)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
|
HUE043879T2
(hu)
|
2011-01-26 |
2019-09-30 |
Glaxosmithkline Biologicals Sa |
RSV-immunizálási rend
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
RU2702501C2
(ru)
|
2011-03-29 |
2019-10-08 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии гена tmprss6
|
DK3275892T3
(da)
|
2011-05-13 |
2020-04-06 |
Glaxosmithkline Biologicals Sa |
Præfusions-rsv-f-antigener
|
EP2714906A1
(de)
|
2011-06-01 |
2014-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur einstellung der expression von mitochondrialem genom durch microrna
|
EP3388068A1
(de)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
CN107201364A
(zh)
|
2011-06-21 |
2017-09-26 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c‑iii(apoc3)基因表达的组合物与方法
|
AU2012272970A1
(en)
|
2011-06-21 |
2014-02-06 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
EP2732038B1
(de)
|
2011-07-15 |
2018-09-05 |
The General Hospital Corporation |
Verfahren zur transkription einer aktivatorähnlichen effektoranordnung
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
CN103917644A
(zh)
|
2011-09-21 |
2014-07-09 |
桑格摩生物科学股份有限公司 |
调控转基因表达的方法和组合物
|
BR112014008694A2
(pt)
|
2011-10-11 |
2017-06-20 |
Novartis Ag |
moléculas de ácido nucleico policistrônico recombinante
|
EP2766385A2
(de)
|
2011-10-12 |
2014-08-20 |
Novartis AG |
Cmv-antigene und verwendungen davon
|
EP2766500A4
(de)
|
2011-10-14 |
2015-10-14 |
Univ Ohio State |
Verfahren und materialien in verbindung mit eierstockkrebs
|
US20140288156A1
(en)
|
2011-10-27 |
2014-09-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the treatment and diagnosis of atherosclerosis
|
WO2013063601A1
(en)
|
2011-10-28 |
2013-05-02 |
University Of Florida Research Foundation, Inc. |
Chimeric promoter for cone photoreceptor targeted gene therapy
|
US8835387B2
(en)
|
2012-02-16 |
2014-09-16 |
Atyr Pharma, Inc. |
Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
|
JP6490426B2
(ja)
|
2012-02-29 |
2019-03-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ハンチントン病を治療するための方法および組成物
|
WO2013152230A1
(en)
|
2012-04-04 |
2013-10-10 |
The Trustees Of Columbia University In The City Of New York |
Smooth muscle specific inhibition for anti-restenotic therapy
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
JP2015518475A
(ja)
|
2012-04-10 |
2015-07-02 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル)Inserm(Institut National Dela Sante Etde La Recherche Medicale) |
非アルコール性脂肪性肝炎の治療方法
|
WO2013153139A1
(en)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and diagnosis of acute leukemia
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
EP2869828B1
(de)
|
2012-07-09 |
2018-01-03 |
The Regents of The University of California |
Vault immuntherapie
|
HUE041553T2
(hu)
|
2012-07-11 |
2019-05-28 |
Sangamo Therapeutics Inc |
Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
|
CA2878037C
(en)
|
2012-07-11 |
2021-08-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
ES2812599T3
(es)
|
2012-08-29 |
2021-03-17 |
Sangamo Therapeutics Inc |
Procedimientos y composiciones para el tratamiento de una afección genética
|
ES2824024T3
(es)
|
2012-10-10 |
2021-05-11 |
Sangamo Therapeutics Inc |
Compuestos modificadores de células T y usos de los mismos
|
EP2906602B1
(de)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
|
LT2929031T
(lt)
|
2012-12-05 |
2018-02-12 |
Alnylam Pharmaceuticals, Inc. |
Pcsk9 irna kompozicijos ir jų naudojimo būdai
|
WO2014089541A2
(en)
|
2012-12-07 |
2014-06-12 |
Haplomics, Inc. |
Factor viii mutation repair and tolerance induction
|
EP2931899A1
(de)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon
|
ES2576128T3
(es)
|
2012-12-12 |
2016-07-05 |
The Broad Institute, Inc. |
Modificación por tecnología genética y optimización de sistemas, métodos y composiciones para la manipulación de secuencias con dominios funcionales
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
ES2658401T3
(es)
|
2012-12-12 |
2018-03-09 |
The Broad Institute, Inc. |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
|
PL2784162T3
(pl)
|
2012-12-12 |
2016-01-29 |
Broad Inst Inc |
Opracowanie systemów, metod oraz zoptymalizowanych kompozycji przewodnikowych do manipulacji sekwencyjnej
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
DK2898075T3
(en)
|
2012-12-12 |
2016-06-27 |
Broad Inst Inc |
CONSTRUCTION AND OPTIMIZATION OF IMPROVED SYSTEMS, PROCEDURES AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
|
PT2921557T
(pt)
|
2012-12-12 |
2016-10-19 |
Massachusetts Inst Technology |
Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
|
EP4234696A3
(de)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Systeme, verfahren und zusammensetzungen mit crispr-cas-komponenten zur sequenzmanipulation
|
EP3623463B1
(de)
|
2013-02-07 |
2021-10-20 |
The General Hospital Corporation |
Tale-transkriptionsaktivatoren
|
CN110938671A
(zh)
|
2013-03-13 |
2020-03-31 |
经纬生物科技有限公司 |
非复制型转导颗粒和基于转导颗粒的报告系统
|
KR102605775B1
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
CA2918194C
(en)
|
2013-03-27 |
2022-12-06 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
CA2910489A1
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
KR102463973B1
(ko)
|
2013-05-22 |
2022-11-07 |
알닐람 파마슈티칼스 인코포레이티드 |
SERPINA1 iRNA 조성물 및 이의 사용 방법
|
SG11201510565TA
(en)
|
2013-05-22 |
2016-01-28 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
CA2913418C
(en)
|
2013-05-29 |
2021-11-23 |
Vybion, Inc. |
Single chain intrabodies that alter huntingtin mutant degradation
|
KR20160030187A
(ko)
|
2013-06-17 |
2016-03-16 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 CRISPRCas 시스템, 벡터 및 조성물의 전달 및 용도
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
EP3011034B1
(de)
|
2013-06-17 |
2019-08-07 |
The Broad Institute, Inc. |
Freisetzung, verwendung und therapeutische anwendungen der crispr-cas-systeme und zusammensetzungen zur abzielung auf störungen und erkrankungen mit viralen komponenten
|
ES2777217T3
(es)
|
2013-06-17 |
2020-08-04 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
DK3011032T3
(da)
|
2013-06-17 |
2020-01-20 |
Broad Inst Inc |
Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til målretning mod og modellering af sygdomme og forstyrrelser i postmitotiske celler
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
CA2920899C
(en)
|
2013-08-28 |
2023-02-28 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
US10077444B2
(en)
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
PE20161130A1
(es)
|
2013-10-04 |
2016-11-25 |
Icahn School Med Mount Sinai |
Composiciones y metodos para inhibir la expresion del gen alas1
|
CN105899665B
(zh)
|
2013-10-17 |
2019-10-22 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
BR112016010175A2
(pt)
|
2013-11-11 |
2017-10-03 |
Sangamo Biosciences Inc |
Repressor genético, seus usos, e composição farmacêutica
|
EP3960856A1
(de)
|
2013-11-13 |
2022-03-02 |
Children's Medical Center Corporation |
Nukleasevermittelte regulierung der genexpression
|
EP3757116A1
(de)
|
2013-12-09 |
2020-12-30 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen für genom-engineering
|
MX2016007327A
(es)
|
2013-12-12 |
2017-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para dirigirlos a trastornos y enfermedades usando componentes para suministro de particulas.
|
WO2015086828A1
(en)
|
2013-12-12 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
|
MX2016007324A
(es)
|
2013-12-12 |
2017-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de los sistemas y composiciones crispr-cas para actuar sobre hbv y trastornos y enfermedades virales.
|
KR20160089527A
(ko)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
게놈 편집을 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료적 응용
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complementary component irna compositions and methods for using them
|
PL3102673T3
(pl)
|
2014-02-03 |
2020-11-02 |
Sangamo Therapeutics, Inc. |
Sposoby i kompozycje do leczenia talasemii beta
|
CN113057959A
(zh)
|
2014-02-11 |
2021-07-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
US9624498B2
(en)
|
2014-03-18 |
2017-04-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
MX2016014565A
(es)
|
2014-05-08 |
2017-05-23 |
Sangamo Biosciences Inc |
Metodos y composiciones para tratar la enfermedad de huntington.
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
JP6811094B2
(ja)
|
2014-05-22 |
2021-01-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アンジオテンシノーゲン(AGT)iRNA組成物およびその使用
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
CA2952697A1
(en)
|
2014-06-16 |
2015-12-23 |
The Johns Hopkins University |
Compositions and methods for the expression of crispr guide rnas using the h1 promoter
|
KR102330593B1
(ko)
|
2014-07-28 |
2021-11-26 |
에스케이이노베이션 주식회사 |
신규 이소프렌 신타아제 및 이를 이용한 이소프렌의 제조방법
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
EP3180426B1
(de)
|
2014-08-17 |
2019-12-25 |
The Broad Institute, Inc. |
Gemonbearbeitung mit cas9-nickasen
|
EP3186368B1
(de)
|
2014-08-25 |
2020-01-15 |
Geneweave Biosciences Inc. |
Nichtreplikative transduktionspartikel und auf transduktionspartikeln basierende reportersysteme
|
CA2957737A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
|
ES2886012T3
(es)
|
2014-09-16 |
2021-12-16 |
Sangamo Therapeutics Inc |
Métodos y composiciones para la ingeniería y corrección de genomas mediadas por nucleasas en células madre hematopoyéticas
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
MX2017005834A
(es)
|
2014-11-05 |
2017-11-17 |
Voyager Therapeutics Inc |
Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
AU2015346162B2
(en)
|
2014-11-14 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
CN112375760A
(zh)
|
2014-11-14 |
2021-02-19 |
沃雅戈治疗公司 |
调节性多核苷酸
|
EP3221451A1
(de)
|
2014-11-17 |
2017-09-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 (apoc3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3985115A1
(de)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Geschützte guide-rnas (pgrnas)
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
EP3256587A2
(de)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing-3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
ES2959608T3
(es)
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composición y métodos de edición del genoma de células B
|
EP4365291A2
(de)
|
2015-06-12 |
2024-05-08 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c5-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
CA3012631A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US20170211142A1
(en)
|
2015-10-22 |
2017-07-27 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
EP3365357B1
(de)
|
2015-10-23 |
2024-02-14 |
President and Fellows of Harvard College |
Entwickelte cas9-proteine für geneditierung
|
CA3006569A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
CN108699132B
(zh)
|
2015-12-18 |
2023-08-11 |
桑格摩生物治疗股份有限公司 |
Mhc细胞受体的靶向破坏
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
US11040114B2
(en)
|
2015-12-24 |
2021-06-22 |
Oxyrane Uk Limited |
Human alpha-N-acetylgalactosaminidase polypeptide
|
EP3402533B1
(de)
|
2016-01-15 |
2021-08-04 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von neurologischer erkrankung
|
JP2019503394A
(ja)
|
2016-01-31 |
2019-02-07 |
ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts |
分岐オリゴヌクレオチド
|
CN109069568B
(zh)
|
2016-02-02 |
2023-07-07 |
桑格摩生物治疗股份有限公司 |
用于连接dna结合结构域和切割结构域的组合物
|
AU2017221441A1
(en)
|
2016-02-17 |
2018-10-04 |
Children's Medical Center Corporation |
FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders
|
EP3445848A1
(de)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Neuartige crispr-enzyme und -systeme
|
CA3026112A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
AU2017257274B2
(en)
|
2016-04-19 |
2023-07-13 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3448987A4
(de)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
SG11201809699XA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
RU2764587C2
(ru)
|
2016-05-18 |
2022-01-18 |
Вояджер Терапьютикс, Инк. |
Способы и композиции для лечения хореи гентингтона
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
CN109790551A
(zh)
|
2016-06-16 |
2019-05-21 |
奥斯陆大学医院Hf |
改进的基因编辑
|
JP7267013B2
(ja)
|
2016-06-17 |
2023-05-01 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Vi型crisprオルソログ及び系
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
MX2019000251A
(es)
|
2016-07-05 |
2019-10-09 |
Univ Johns Hopkins |
Composiciones y metodos que comprenden mejoras de los arn guias de crispr usando el promotor h1.
|
US11124805B2
(en)
|
2016-07-13 |
2021-09-21 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
CA3030587A1
(en)
|
2016-07-15 |
2018-01-18 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
AU2017306676B2
(en)
|
2016-08-03 |
2024-02-22 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
AU2017315414B2
(en)
|
2016-08-24 |
2024-02-15 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
WO2018039440A1
(en)
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
US11298041B2
(en)
|
2016-08-30 |
2022-04-12 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
CA3039673A1
(en)
|
2016-10-20 |
2018-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
US11020492B2
(en)
|
2016-10-31 |
2021-06-01 |
Sangamo Therapeutics, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
JP7416406B2
(ja)
|
2016-12-08 |
2024-01-17 |
ケース ウェスタン リザーブ ユニバーシティ |
機能的ミエリン産生を増進させるための方法および組成物
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
WO2018195338A1
(en)
|
2017-04-20 |
2018-10-25 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症(als)治療組成物および方法
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
US11872262B2
(en)
|
2017-05-09 |
2024-01-16 |
Vib Vzw |
Means and methods for treating bacterial infections
|
US20210278416A1
(en)
|
2017-05-09 |
2021-09-09 |
The Broad Institute, Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
WO2018236548A1
(en)
|
2017-06-23 |
2018-12-27 |
Inscripta, Inc. |
NUCLEIC ACID GUIDED NUCLEASES
|
AU2018290843A1
(en)
|
2017-06-26 |
2020-01-16 |
Massachusetts Institute Of Technology |
CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
US10392616B2
(en)
|
2017-06-30 |
2019-08-27 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
KR20200044793A
(ko)
|
2017-08-03 |
2020-04-29 |
보이저 테라퓨틱스, 인크. |
Aav의 전달을 위한 조성물 및 방법
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
CN111511388A
(zh)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
用于靶向核酸编辑的系统、方法和组合物
|
JP2021502060A
(ja)
|
2017-10-16 |
2021-01-28 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症(als)の治療
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
US11866701B2
(en)
|
2017-11-01 |
2024-01-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
WO2019143677A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
BR112020014140A2
(pt)
|
2018-01-17 |
2020-12-01 |
Vertex Pharmaceuticals Incorporated |
inibidores de dna-pk
|
AU2019209293B2
(en)
|
2018-01-17 |
2023-07-27 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
WO2019160383A1
(ko)
|
2018-02-19 |
2019-08-22 |
고려대학교 산학협력단 |
열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
|
EP3765616B1
(de)
|
2018-03-14 |
2023-07-19 |
Arbor Biotechnologies, Inc. |
Neuartige, auf dna und rna gerichtete crispr enzyme und systeme
|
EP4257696A3
(de)
|
2018-03-14 |
2024-01-24 |
Arbor Biotechnologies, Inc. |
Neuartige, auf dna gerichtete crispr enzyme und systeme
|
WO2019217943A1
(en)
|
2018-05-11 |
2019-11-14 |
Beam Therapeutics Inc. |
Methods of editing single nucleotide polymorphism using programmable base editor systems
|
EP3797160A1
(de)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Baseneditoren und verwendungen davon
|
SG11202011975WA
(en)
|
2018-06-05 |
2020-12-30 |
Lifeedit Inc |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2020018142A1
(en)
|
2018-07-16 |
2020-01-23 |
Arbor Biotechnologies, Inc. |
Novel crispr dna targeting enzymes and systems
|
WO2020033601A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
EP3837367A1
(de)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
CN113015741A
(zh)
|
2018-09-18 |
2021-06-22 |
桑格摩生物治疗股份有限公司 |
程序性细胞死亡1(pd1)特异性核酸酶
|
WO2020079033A1
(en)
|
2018-10-15 |
2020-04-23 |
Fondazione Telethon |
Genome editing methods and constructs
|
TW202028461A
(zh)
|
2018-10-18 |
2020-08-01 |
美商英特利亞醫療公司 |
核酸構築體及使用方法
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
CN113166760A
(zh)
|
2018-11-23 |
2021-07-23 |
赛诺菲 |
用于抑制angptl8的新型rna组合物和方法
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
JP2022515451A
(ja)
|
2018-12-27 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
アシネトバクター・バウマンニの検出のための、非複製的形質導入粒子及び形質導入粒子に基づくレポーター系
|
MX2021007835A
(es)
|
2018-12-27 |
2021-08-11 |
Lifeedit Therapeutics Inc |
Polipeptidos utiles para edicion de genes y metodos de uso.
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
JP2022526908A
(ja)
|
2019-03-19 |
2022-05-27 |
ザ ブロード インスティテュート,インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
CA3131759A1
(en)
|
2019-04-09 |
2020-10-15 |
Prashant MALI |
Long-lasting analgesia via targeted in vivo epigenetic repression
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
WO2020212586A1
(en)
|
2019-04-18 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and prognosis of cancer
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
WO2020243485A1
(en)
|
2019-05-29 |
2020-12-03 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
WO2021016075A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
US20220315906A1
(en)
|
2019-08-08 |
2022-10-06 |
The Broad Institute, Inc. |
Base editors with diversified targeting scope
|
EP4013864A1
(de)
|
2019-08-12 |
2022-06-22 |
Lifeedit Therapeutics, Inc. |
Rna-gesteuerte nukleasen, aktive fragmente und varianten davon und verwendungsverfahren
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
CN114616331A
(zh)
|
2019-09-03 |
2022-06-10 |
阿尔尼拉姆医药品有限公司 |
抑制lect2基因表达的组合物和方法
|
CA3153563A1
(en)
|
2019-09-09 |
2021-03-18 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
EP4028064A1
(de)
|
2019-09-12 |
2022-07-20 |
The Broad Institute, Inc. |
Manipulierte adeno-assoziierte viruskapside
|
EP4038189A1
(de)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
JP2023502038A
(ja)
|
2019-11-13 |
2023-01-20 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アンギオテンシノーゲン(agt)関連障害を処置するための方法および組成物
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
WO2021138247A1
(en)
|
2019-12-30 |
2021-07-08 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2021136752A1
(en)
|
2019-12-31 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
WO2021155065A1
(en)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
EP4100519A2
(de)
|
2020-02-05 |
2022-12-14 |
The Broad Institute, Inc. |
Adeninbaseneditoren und verwendungen davon
|
WO2021158999A1
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
KR20230008729A
(ko)
|
2020-04-06 |
2023-01-16 |
알닐람 파마슈티칼스 인코포레이티드 |
Myoc 발현을 사일런싱하기 위한 조성물 및 방법
|
WO2021207189A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
TW202208626A
(zh)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna引導核酸酶及其活性片段與變體,以及使用方法
|
EP4143315A1
(de)
|
2020-04-28 |
2023-03-08 |
The Broad Institute Inc. |
<smallcaps/>?ush2a? ?gezielte basisbearbeitung eines thegens
|
JP2023525510A
(ja)
|
2020-05-06 |
2023-06-16 |
セレクティス ソシエテ アノニム |
治療用タンパク質の送達のために細胞を遺伝子改変する方法
|
JP2023525513A
(ja)
|
2020-05-06 |
2023-06-16 |
セレクティス ソシエテ アノニム |
細胞ゲノムにおける外因性配列の標的化挿入のための方法
|
AU2021267940A1
(en)
|
2020-05-08 |
2022-12-08 |
President And Fellows Of Harvard College |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
WO2021231437A1
(en)
|
2020-05-11 |
2021-11-18 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
AU2021310363A1
(en)
|
2020-07-15 |
2023-03-16 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
WO2022034374A2
(en)
|
2020-08-11 |
2022-02-17 |
University Of Oslo |
Improved gene editing
|
WO2022046760A2
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
WO2022056254A2
(en)
|
2020-09-11 |
2022-03-17 |
LifeEDIT Therapeutics, Inc. |
Dna modifying enzymes and active fragments and variants thereof and methods of use
|
CA3197730A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffman-La Roche Ag |
Nucleic acid constructs for va rna transcription
|
KR20230085170A
(ko)
|
2020-10-15 |
2023-06-13 |
에프. 호프만-라 로슈 아게 |
동시 유전자 활성화를 위한 핵산 구조체
|
WO2022079221A1
(en)
|
2020-10-16 |
2022-04-21 |
Sanofi |
Rna compositions and methods for inhibiting lipoprotein(a)
|
JP2023546103A
(ja)
|
2020-10-16 |
2023-11-01 |
サノフイ |
Angptl3を阻害するための新規のrna組成物および方法
|
EP4232581A1
(de)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
CA3173950A1
(en)
|
2021-03-22 |
2022-09-22 |
Tyson D. BOWEN |
Dna modifyng enzymes and active fragments and variants thereof and methods of use
|
CN117529555A
(zh)
|
2021-03-23 |
2024-02-06 |
比姆医疗股份有限公司 |
新颖crispr酶、方法、系统及其用途
|
CA3215435A1
(en)
|
2021-04-16 |
2022-10-20 |
Giuseppe Ciaramella |
Genetic modification of hepatocytes
|
EP4341300A1
(de)
|
2021-05-21 |
2024-03-27 |
Cellectis S.A. |
Erhöhung der wirksamkeit von t-zell-vermittelter immuntherapie durch modulation von krebsassoziierten fibroblasten in soliden tumoren
|
EP4349979A1
(de)
|
2021-05-27 |
2024-04-10 |
Institute Of Zoology, Chinese Academy Of Sciences |
Manipulierte cas12i-nuklease, effektorprotein und verwendung davon
|
CA3173953A1
(en)
|
2021-06-11 |
2023-12-10 |
Tyson D. BOWEN |
Rna polymerase iii promoters and methods of use
|
WO2022261509A1
(en)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
WO2023278576A1
(en)
|
2021-06-30 |
2023-01-05 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023004367A2
(en)
|
2021-07-20 |
2023-01-26 |
The Broad Institute, Inc. |
Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
CN114015674A
(zh)
|
2021-11-02 |
2022-02-08 |
辉二(上海)生物科技有限公司 |
新型CRISPR-Cas12i系统
|
WO2023114953A2
(en)
|
2021-12-17 |
2023-06-22 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023139557A1
(en)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2023196802A1
(en)
|
2022-04-04 |
2023-10-12 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
WO2023196772A1
(en)
|
2022-04-04 |
2023-10-12 |
Beam Therapeutics Inc. |
Novel rna base editing compositions, systems, methods and uses thereof
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
US20230366001A1
(en)
|
2022-05-12 |
2023-11-16 |
SunVax mRNA Therapeutics Inc. |
Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
|
WO2023225564A1
(en)
|
2022-05-18 |
2023-11-23 |
The Broad Institute, Inc. |
Engineered viral capsids with increased stability and methods of use thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023227438A1
(en)
|
2022-05-23 |
2023-11-30 |
F. Hoffmann-La Roche Ag |
Raman-based method for the differentiation of aav particle serotype and aav particle loading status
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024056561A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
Method for separating full and empty aav particles
|
WO2024059791A1
(en)
|
2022-09-16 |
2024-03-21 |
Beam Therapeutics Inc. |
Large serine recombinases, systems and uses thereof
|